Pathios brings together a team of experienced scientific leaders and drug discovery professionals to deliver on the therapeutic promise of targeting the innate immune system in cancer. Pathios also benefits from being part of the M:M Bio (Molecule 2 Medicine) ecosystem which is focused on drug discovery company ideation, creation, incubation, and growth. M:M Bio provides organisations like Pathios with operational and R&D support to help them achieve scientific, clinical & commercial success. For more information see www.molecule2medicine.com.
Stuart is Chief Executive Officer of Pathios and brings over 20 years experience in scientific leadership and drug discovery expertise. Stuart has worked across several therapeutic areas inlcuding CNS disorders, immunology and oncology and has deep expertise in guiding early stage drug discovery programs from inception toward clinical development. Stuart has gained wide-ranging experience from positions in both academic and industrial settings. Previous positions include Research Fellow and Senior Lecturer at Cardiff University, Principal Research Scientist at Eli Lilly and most recently, Senior Director at Vertex Pharmaceuticals. He holds a a PhD in Neuroscience from Cardiff University, a BSc in Pure and Applied Mathematics and an MSc in Electronic Engineering. Stuart is also a director at M:M Bio.
Tom is a Co-Founder and Executive Chairperson of Pathios Therapeutics and brings over 25 years of experience in drug discovery, development and commercialization to the team. Pathios Therapeutics was created and incubated within M:M Bio Limited (Molecule 2 Medicine), a U.K.-based biotechnology hub that leverages its unique ecosystem to build enduring, commercially orientated drug discovery and development companies. Tom is Co-Founder and Chairperson of M:M Bio and also Co-Founder and Executive Chairperson of two additional biotechnology companies that are part of the overall M:M Bio hub; Grey Wolf Therapeutics and ThirtyFiveBio. His additional roles include Chair of Orbit Discovery and Venture Partner at Brandon Capital. Prior to his leadership positions within the M:M Bio hub, he was President and CEO of Spinifex Pharmaceuticals, a private VC backed US/Australian biotech company developing first in class treatments for chronic pain, devoid of central nervous system side-effects. Spinifex Pharmaceuticals was purchased by Novartis in 2015 for approximately US$700 million. Previous positions include Vice President of Drug Development at Starpharma Holdings Limited (Australia). He holds BSc (Hons) and PhD degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.
Shelley has built out and led Operations and championed a culture to support high-performing teams in a number of growing Biotechs and business units. She also has demonstrable Strategic, Licencing and Alliance Management experience at senior level. Prior to this, Shelley was a Life Science Equity Research Analyst. She graduated with a BA and MSc in Bioscience and DPhil in Emerging Tropical Viruses from University of Oxford, UK, and completed her post-doctoral studies as a Sir Henry Wellcome Fellow at the Natural History Museum, UK and Aix Marseille Université, France.
Kirsty is Co-founder at Pathios and CEO of M:M Bio. Kirsty has a track record in founding and running two companies based on intellectual property from Australia’s then government funded telecommunications research laboratory in the areas of voice recognition and the analysis of “big data”, the latter directly relevant to bioinformatics applications in life science companies. She is an MBA graduate from University of Melbourne following undergraduate studies at Monash University and The University of Queensland.
David is the VP of Drug Discovery at Pathios and brings 25 years of experience to the company in terms of designing potent and novel molecules, DMPK, IP, project leadership and compound progression into clinical trials. Working across multiple therapeutic areas, David has previously held positions at Organon Laboratories in Scotland and at Amedis Pharmaceuticals, Paradigm Therapeutics and Takeda in Cambridge. Most recently David was a key member of the team at Inflazome which delivered two compounds into clinical trials and was recently acquired by Roche.
Barbara is Head of Biology at Pathios. She has a PhD in Immunology and brings over 17 years’ experience in drug discovery, gained first at MSD then at Vertex Pharmaceuticals. At MSD she worked on developing anti-cancer vaccines and immuno-oncology assets. She then joined Vertex Pharmaceuticals where she led immunology efforts in the areas of inflammation, autoimmunity and immuno-oncology. In this role she set-up complex immunological assays and developed biomarkers to advance drug candidates. More recently at Vertex Barbara served as project leader, managing programs related to rare CNS disorders involving inflammation and autoimmunity. She also led a team to establish in vitro disease models using human pluripotent stem cells and gene editing to support additional programs.
Alan is Head of Drug Discovery and Co-founder at Pathios. Alan is a medicinal chemist with over 30 years experience in Research and Development within GlaxoSmithKline. He previously held the position of Vice President and Director of Medicinal Chemistry within the GSK Drug Discovery organization and has led strategic, matrix and line functions involving significant international responsibilities. He has an extensive track record of success, across a wide range of therapeutic areas, having played a major role in the discovery of over 30 development compounds, and is a co-inventor of Serevent, a major advance in the treatment of asthma. Alan also acts an independent consultant providing scientific and strategic advice and analysis to major pharma, biotechnology companies, academic groups, capital investment companies and funding bodies on a variety of issues within the drug discovery and healthcare sector.
Alastair is a Senior Scientist at Pathios, and brings nearly 10 years of experience in biomedical research & drug discovery across inflammatory, cardiovascular, and neuropathic disease. At Pathios, Alastair provides expertise in mononuclear phagocyte immunology, flow cytometry, and in vivo models to support and direct R&D activities. Before joining Pathios, Alastair worked at Ipsen Bioinnovation where he advanced the neurotoxin portfolio by designing and conducting biological and biophysical assays to determine efficacy and binding properties of modified recombinant neurotoxins. Prior to Ipsen, Alastair spent 6 years researching innate immunology, investigating the role of IRF5 in directing intestinal inflammation and repurposing an existing small molecule for the treatment of inflammatory bowel disease. Alastair holds a DPhil in Cellular and Molecular Medicine from University of Oxford, and a BSc(Hons) in Medical Biochemistry from University of Manchester.
Faraz is a Senior Bioinformatician at M:M Bio Ltd. He is responsible for the development of bioinformatic pipelines and novel computational methods for diverse multi-omic datasets to provide unique biological insight for ongoing drug discovery and development programs. His passion is to use computational approaches to understand complex diseases, with an aim to deliver first-in-class medicines, ultimately improving patient lives. He has over 5 years of experience, which includes working for both biotech industry and academic sectors, where he provided computational expertise in the biomarker identification to understand disease mechanisms. Faraz attained MRes, PhD degrees from the University of Nottingham, UK.
Maria Jose is a Project Manager at Pathios and has over 10 years of experience in biomedical research in inflammation and immuno oncology. She is a certified agile project manager (PSK) and has extensive experience in establishing scientific collaborations, developing supplier relationships and fostering a culture of continuous improvement. At Pathios, she manages key supplier relationships to keep R&D studies and programs progressing in line with scientific aims, corporate goals and financial budgets. Prior to joining Pathios, Maria Jose was a Preclinical Senior Scientist at Immunocore Ltd. Maria Jose holds a PhD in Biomedicine and Molecular Biology from the University of Seville, an MPhil in Translational Medicine and Therapeutics from the University of Cambridge and a Bsc(Hons) in Pharmacy from the University of Seville.
Sam is currently Project Manager at Pathios supporting both the R&D and operations teams. He provides project management across various CROs, studies and partners. Prior to joining Pathios, Sam worked as a Conference Producer at Hanson Wade for 2 years where he lead the research, production and management of market-leading conferences in the cell immunotherapy space. Sam holds a MSci (Hons) in Chemistry from University College London.
Tino is a graduate from the University of Westminster with a BSc (Hons) in Biomedical Science. Alongside her studies into computational analysis of viral nucleoproteins, she was part of university funded research projects based on human genetics. In her role as Biotech Associate, she facilitates the innovation, execution and support of multiple company projects and assists both the Operational and R&D teams at Pathios.
Peter is an advisor to Pathios and co-founder. He is also co-founder and Chief Executive Officer of Grey Wolf Therapeutics and has over 13 years of experience in biomedical research leading drug discovery projects in immuno-oncology, rare genetic diseases and neurodegeneration. In his most recent role at Vertex Pharmaceuticals, he led drug discovery projects, had responsibility for leading a number of target identification teams that led to multiple novel drug discovery projects and was involved in delivering clinical drug candidates. He also pioneered the development of complex neurological assays suitable for assessing the functional impact of optimized compounds. Prior to Vertex, Peter was an MRC Research Fellow investigating the pathophysiology and underlying mechanisms of neurodegeneration and publishing multiple first and co-author publications. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.
James is an adviser to Pathios and is also Chief Executive Officer of ThirtyFiveBio and a director at M:M Bio. James brings over 20 years of drug discovery industry experience working in therapeutic areas such as oncology, immuno-oncology and rare disease to enable target identification, validation and clinical candidate delivery. Previous positions include being part of the research leadership team at Vertex Pharmaceuticals’ Oxford research centre, project leader/lead biologist on various discovery projects and head of the primary pharmacology, enzymology and high-throughput screening groups. James has worked extensively on small molecule modality projects and recently with PROTAC and anti-sense oligonucleotide approaches against a range of targets including enzymes, GPCRs and ion channels. James received his PhD in Biochemistry from the University of Bristol and 1st class honours BSc in Chemistry from the University of Aston.
Sam Harris is the Company Secretary for M:M Bio. She graduated from Aston University in 1999 with a BSc with Honours degree in International Business and Modern Languages (French), which included a year at one of France’s top Business Schools – EDHEC.
Lisa is Finance Manager at M:M Bio. Having completed a BA (Hons) in Accountancy & Management Control, Lisa qualified as a Chartered Accountant ICAEW with Mazars in 2000. Since qualifying, Lisa has held various finance and operational roles within both the private and public sector with a focus on working with SMEs and she brings this experience with her to her role here.
With over 25 years working as an HR specialist, Andrea has successfully delivered projects around organisation design, TUPE, large scale redundancies, performance design, culture and employee engagement, leadership and employee development. Previously, Andrea worked for Berendsen UK Ltd as HR Director for the Hospitality Business Line where she was responsible for the HR function for 3000 employees across UK, Ireland, Denmark and Sweden. Andrea is a Chartered Member of the CIPD, a Mental Health First Aider and a registered practitioner in DISC and Hogan psychometric testing.
Phill is the Business Intelligence Manager for M:M Bio where he provides commercial insight for the group. In his role, he is responsible for strategy, market & financial analytics, and competitive intelligence. Phill has a background in consumer business and tech, working in large multinational companies in a variety of commercial sales and project management roles, as well and more recently in the Canadian tech startup ecosystem as product manager. Originally from New Zealand, Phill has just moved to Oxford UK from Vancouver. He is an MBE (Bioscience Enterprise) graduate from the University of Cambridge, with prior undergraduate studies at the Otago University in Chemistry and Business.
Sean is an International Business BSc (Hons) graduate from Oxford Brookes University and is Executive Assistant at Pathios. Sean has over 10 years experience in hospitality and customer relations, as well as supporting C-Suite executives across both public and private sector organisations.
Amanda is a highly skilled and experienced Bookkeeper who holds an AAT qualification. She has extensive knowledge having worked in various finance and operational roles across the corporate sector for SMEs. At Pathios, Amanda is responsible for supporting finance processes and systems that aid the decision-making and ensuring that Pathios achieves its strategic goals.